Serina Therapeutics annual gross margin
2017
2018
2019
2020
2021
2022
2023
Serina Therapeutics Gross Margin Growth & History (SER)
Serina Therapeutics's gross margin was 3.24% for fiscal 2023.
View full Serina Therapeutics company overviewSerina Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | 3.24% | −58.53 pp |
| 2022 | 2022-12-31 | 61.76% | −25.04 pp |
| 2021 | 2021-12-31 | 86.81% | −5.99 pp |
| 2020 | 2020-12-31 | 92.80% | +6.92 pp |
| 2019 | 2019-12-31 | 85.88% | +11.95 pp |
| 2018 | 2018-12-31 | 73.93% | −14.11 pp |
| 2017 | 2017-12-31 | 88.03% | — |
Serina Therapeutics quarterly gross margin
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2023 | 2023-12-31 | 1.78% | −85.72 pp |
| Q3 2023 | 2023-09-30 | 117.24% | +72.80 pp |
| Q2 2023 | 2023-06-30 | 57.14% | +7.14 pp |
| Q1 2023 | 2023-03-31 | 30.00% | −50.00 pp |
| Q4 2022 | 2022-12-31 | 87.50% | −8.80 pp |
| Q3 2022 | 2022-09-30 | 44.44% | −47.22 pp |
| Q2 2022 | 2022-06-30 | 50.00% | −14.86 pp |
| Q1 2022 | 2022-03-31 | 80.00% | −14.64 pp |
| Q4 2021 | 2021-12-31 | 96.30% | −0.54 pp |
| Q3 2021 | 2021-09-30 | 91.67% | +16.30 pp |
| Q2 2021 | 2021-06-30 | 64.86% | −28.47 pp |
| Q1 2021 | 2021-03-31 | 94.64% | −4.23 pp |
| Q4 2020 | 2020-12-31 | 96.84% | +11.23 pp |
| Q3 2020 | 2020-09-30 | 75.36% | −12.72 pp |
| Q2 2020 | 2020-06-30 | 93.33% | +7.28 pp |
| Q1 2020 | 2020-03-31 | 98.88% | +15.11 pp |
| Q4 2019 | 2019-12-31 | 85.61% | +43.12 pp |
| Q3 2019 | 2019-09-30 | 88.08% | −12.97 pp |
| Q2 2019 | 2019-06-30 | 86.05% | +3.08 pp |
| Q1 2019 | 2019-03-31 | 83.76% | +29.37 pp |
| Q4 2018 | 2018-12-31 | 42.49% | — |
| Q3 2018 | 2018-09-30 | 101.05% | — |
| Q2 2018 | 2018-06-30 | 82.97% | — |
| Q1 2018 | 2018-03-31 | 54.39% | — |
Serina Therapeutics gross margin trends
Over the last five reported fiscal years, Serina Therapeutics's gross margin decreased from 73.93% to 3.24%, a change of −70.69 percentage points. The latest reported quarter, Q4 2023, shows 1.78%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Serina Therapeutics filings at SEC.gov ↗